The effect of I.V. L-NG Methylarginine Hydrochloride (L-NMMA: 546C88) on Basal and Acetazolamide (Diamox®) induced Changes of Blood Velocity in Cerebral Arteries and Regional Cerebral Blood flow in Man

Cephalalgia ◽  
2005 ◽  
Vol 25 (5) ◽  
pp. 344-352 ◽  
Author(s):  
LH Lassen ◽  
B Sperling ◽  
AR Andersen ◽  
J Olesen
Keyword(s):  
Blood Flow ◽  
Cerebral Blood Flow ◽  
Regional Cerebral Blood Flow ◽  
Cerebral Arteries ◽  
Blood Velocity ◽  
Percentage Increase ◽  
Regional Cerebral Blood ◽  
Cerebral Arterioles ◽  
Induced Changes ◽  
Oxide Synthase

The aim of this study was to estimate the effect of Nitric Oxide synthase (NOS)-inhibition (L-NMMA) on the diameter of the middle cerebral artery (MCA) and on regional cerebral blood flow (rCBF). Furthermore, to assess the effect of L-NMMA on acetazolamide induced increases in MCA blood velocity (Vmean) and rCBF. In an open crossover design 12 healthy subjects attended the laboratory twice. The first day 6 mg/kg L-LNMMA i.v. over 15 min preceded 1 g acetazolamide iv over 5 min. Eight days later only acetazolamide was given. Vmean in MCA was determined with transcranial Doppler (TCD) and rCBF with Xe-133 inhalation SPECT at baseline, after L-NMMA and 25 and 55 min after acetazolamide infusion. After L-NMMA the decrease in rCBFMCA was 6.8% (± 7.4) ( P < 0.019, n = 12), whereas Vmean was not affected ( P = 0.83, n = 8). The change in MCA diameter was estimated to -1.3% ( P = 0.44, n = 8). L-NMMA did not affect acetazolamide increases in Vmean ( P = 0.67, n = 8) nor rCBF ( P = 0.29, n = 12). The percentage increase of Vmean was 1.5 times that of rCBF ( n = 8). Our data suggest that the basal tone of human cerebral arterioles but not of conduit arteries is NO-dependent. The action of acetazolamide in man is not NO-dependent.

scholarly journals Regional Cerebral Blood Flow, Cerebral Blood Velocity, and Pulsatility Index in Newborn Dogs

1983 ◽  
Vol 17 (11) ◽  
pp. 908-912 ◽  
Author(s):  
Daniel G Batton ◽  
Jonathan Hellmann ◽  
Milton J Hernandez ◽  
M Jeffrey Maisels
Keyword(s):  
Blood Flow ◽  
Cerebral Blood Flow ◽  
Pulsatility Index ◽  
Regional Cerebral Blood Flow ◽  
Blood Velocity ◽  
Regional Cerebral Blood ◽  
Cerebral Blood Velocity

scholarly journals Effects of route of administration on oxytocin-induced changes in regional cerebral blood flow in humans

2019 ◽  
Author(s):  
D. A. Martins ◽  
N. Mazibuko ◽  
F. Zelaya ◽  
S. Vasilakopoulou ◽  
J. Loveridge ◽  
...  
Keyword(s):  
Blood Flow ◽  
Cerebral Blood Flow ◽  
Regional Cerebral Blood Flow ◽  
Systemic Circulation ◽  
Brain Regions ◽  
Regional Cerebral Blood ◽  
Intranasal Route ◽  
Brain Physiology ◽  
Induced Changes ◽  
Robust Evidence

ABSTRACTCould nose-to-brain pathways mediate the effects of peptides such as oxytocin (OT) on brain physiology when delivered intranasally? We address this question by contrasting two methods of intranasal administration (a standard nasal spray, and a nebulizer expected to improve OT deposition in nasal areas putatively involved in direct nose-to-brain transport) to intravenous administration in terms of effects on regional cerebral blood flow during two hours post-dosing. We demonstrate that OT-induced decreases in amygdala perfusion, a key hub of the OT central circuitry, are explained entirely by OT increases in systemic circulation following both intranasal and intravenous OT administration. Yet we also provide robust evidence confirming the validity of the intranasal route to target specific brain regions. Our work has important translational implications and demonstrates the need to carefully consider the method of administration in our efforts to engage specific central oxytocinergic targets for the treatment of neuropsychiatric disorders.

Methylphenidate-induced changes in regional cerebral blood flow: A [15O]H2O PET study in healthy volunteers

2005 ◽  
Vol 25 (1_suppl) ◽  
pp. S340-S340
Author(s):  
Joanna I Udo de Haes ◽  
Paul Maguire ◽  
Anne M J Paans ◽  
Piet L Jager ◽  
Johan A den Boer
Keyword(s):  
Blood Flow ◽  
Cerebral Blood Flow ◽  
Healthy Volunteers ◽  
Regional Cerebral Blood Flow ◽  
Regional Cerebral Blood ◽  
Induced Changes

Effect of acetazolamide on cerebral artery blood velocity and regional cerebral blood flow in normal subjects

1989 ◽  
Vol 97 (3-4) ◽  
pp. 139-145 ◽  
Author(s):  
W. Sorteberg ◽  
K. -F. Lindegaard ◽  
K. Rootwelt ◽  
A. Dahl ◽  
R. Nyberg-Hansen ◽  
...  
Keyword(s):  
Blood Flow ◽  
Cerebral Blood Flow ◽  
Cerebral Artery ◽  
Regional Cerebral Blood Flow ◽  
Normal Subjects ◽  
Blood Velocity ◽  
Regional Cerebral Blood

scholarly journals The Phosphodiesterase 3 Inhibitor Cilostazol Dilates Large Cerebral Arteries in Humans without Affecting Regional Cerebral Blood Flow

2004 ◽  
Vol 24 (12) ◽  
pp. 1352-1358 ◽  
Author(s):  
Steffen Birk ◽  
Christina Kruuse ◽  
Kenneth A. Petersen ◽  
Olga Jonassen ◽  
Peer Tfelt-Hansen ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Blood Flow ◽  
Cerebral Blood Flow ◽  
Cerebral Vasospasm ◽  
Regional Cerebral Blood Flow ◽  
Cerebral Arteries ◽  
Superficial Temporal Artery ◽  
Mean Flow ◽  
Regional Cerebral Blood ◽  
Delayed Cerebral Vasospasm

Cilostazol, an inhibitor of phosphodiesterase (PDE) type 3, is used clinically in peripheral artery disease. PDE3 inhibitors may be clinically useful in the treatment of delayed cerebral vasospasm after subarachnoid hemorrhage. The authors present the first results on the effect of cilostazol on cerebral hemodynamics in normal participants. In this double-blind, randomized, crossover study, 200 mg cilostazol or placebo was administered orally to 12 healthy participants. Cerebral blood flow was measured using 133Xe inhalation and single photon emission computerized tomography. Mean flow velocity in the middle cerebral arteries (VMCA) was measured with transcranial Doppler, and the superficial temporal and radial arteries diameters were measured with ultrasonography. During the 4-hour observation period, there was no effect on systolic blood pressure ( P = 0.28), but diastolic blood pressure decreased slightly compared with placebo ( P = 0.04). VMCA decreased 21.5 ± 5.7% after cilostazol and 5.5 ± 12.2% after placebo ( P = 0.02, vs. placebo), without any change in global or regional cerebral blood flow. The superficial temporal artery diameter increased 17.6 ± 12.3% ( P < 0.001 vs. baseline) and radial artery diameter increased 12.6 ± 8.6% ( P < 0.001 vs. baseline). Adverse events, especially headache, were common. The findings suggest that cilostazol is an interesting candidate for future clinical trials of delayed cerebral vasospasm.

Sign in / Sign up

Export Citation Format

Share Document